Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:701088rdf:typepubmed:Citationlld:pubmed
pubmed-article:701088lifeskim:mentionsumls-concept:C0043157lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0024554lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0017890lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0042285lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0181586lld:lifeskim
pubmed-article:701088lifeskim:mentionsumls-concept:C0170562lld:lifeskim
pubmed-article:701088pubmed:issue4lld:pubmed
pubmed-article:701088pubmed:dateCreated1978-12-27lld:pubmed
pubmed-article:701088pubmed:abstractTextA second instance of the unstable mutant Hb Nottingham (alpha2beta2 (FG5) 98 Val leads to Gly) is reported in a 7-year-old boy. Because of splenomegaly, cholelithiasis, and frequent episodes of abdominal pain, he underwent a splenectomy and cholecystectomy at age 6. The surgery resulted in both an amelioration of his RBC destruction and an acceleration of his rate of growth.lld:pubmed
pubmed-article:701088pubmed:languageenglld:pubmed
pubmed-article:701088pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:701088pubmed:citationSubsetIMlld:pubmed
pubmed-article:701088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:701088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:701088pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:701088pubmed:statusMEDLINElld:pubmed
pubmed-article:701088pubmed:issn0363-0269lld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:WilsonJ BJBlld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:HuismanT HTHlld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:OrringerE PEPlld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:GravelyM EMElld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:LaiDDlld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:ReeseAAlld:pubmed
pubmed-article:701088pubmed:authorpubmed-author:FeliceAAlld:pubmed
pubmed-article:701088pubmed:issnTypePrintlld:pubmed
pubmed-article:701088pubmed:volume2lld:pubmed
pubmed-article:701088pubmed:ownerNLMlld:pubmed
pubmed-article:701088pubmed:authorsCompleteYlld:pubmed
pubmed-article:701088pubmed:pagination315-32lld:pubmed
pubmed-article:701088pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-H...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-H...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-S...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-C...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-G...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-V...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-H...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-M...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-C...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-R...lld:pubmed
pubmed-article:701088pubmed:meshHeadingpubmed-meshheading:701088-H...lld:pubmed
pubmed-article:701088pubmed:year1978lld:pubmed
pubmed-article:701088pubmed:articleTitleHb Nottingham (alpha2beta2 (FG5) 98 val leads to gly) in a Caucasian male: clinical and biosynthetic studies.lld:pubmed
pubmed-article:701088pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:701088pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:701088pubmed:publicationTypeCase Reportslld:pubmed